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Hypoxia in tumours is recognized as a potential cause for resis-
tance to radiotherapy. The modulation of radiosensitivity by
oxygen (O2) is best established for cultured mammalian cells,
which are highly resistant to the cytotoxic effects of ionizing
radiation under conditions of extremely low partial pressures of
oxygen (pO2) of ≤3 mmHg (Hall, 1994). The correlation between
tumour control probability and haemoglobin (Hb) concentration
also lends indirect evidence to the importance of oxygen delivery
as a determinant of radiotherapeutic outcome (Evans and Bergsjo,
1965; Bush et al, 1978; Overgaard et al, 1989). Furthermore,
clinical studies involving pretreatment interstitial measurements of
pO2 in squamous cell carcinomas of the uterine cervix and the
head and neck region have demonstrated an inverse relationship
between the extent of tumour hypoxia and tumour control rates
after radiotherapy (Gatenby et al, 1988; Hockel et al, 1993;
Nordsmark et al, 1996a; Brizel et al, 1997).
In an attempt to sensitize tumours to radiotherapy, different
techniques for targeting hypoxic cells or improving delivery of
oxygen have been used. A meta-analysis of randomized studies
involving hypoxic cell radiosensitization via nitroimidazoles
revealed significant, albeit small, improvement in local control
and survival in patients with head and neck and bladder carci-
nomas (Overgaard, 1994). The use of hyperbaric oxygen as an
adjuvant to radiotherapy for locally advanced cervical cancer was
evaluated in several randomized studies, but a benefit was not
consistently observed (Fletcher et al, 1977; Ward and Dixon, 1979;
Dische, 1983; Brady et al, 1981). An alternative approach to
improved oxygen delivery to tumour tissues is to exploit the enor-
mous reservoir of oxygen that remains bound to Hb even after
passage of blood through the capillary bed. Pioneering efforts to
achieve additional unloading of oxygen from Hb included the use
of 2,3-diphosphoglycerol (2,3-DPG) and chlorophenoxy acetic
acid derivatives (Siemann et al, 1979; Siemann and Macler, 1986;
Hirst and Wood 1987, 1989; Hirst et al, 1987), but did not reach
clinical application.
Synthetic allosteric effectors of Hb have now been developed as
a new class of pharmaceutical agents for potential therapeutic
application in conditions of detrimental tissue hypoxia. One of
these compounds, 2-[4-(((3,5-dimethylanilino)carbonyl)methyl)-
phenoxy]-2-methylpropionic acid (RSR13) stabilizes Hb in the
deoxy state which results in reduced Hb–O2 affinity (Randad et al,
1991; Wireko et al, 1991; Abraham et al, 1992a, b). This effect of
Hb–O2 affinity is quantifiable as an increase in p50, defined as the
pO2 required for 50% saturation of Hb binding sites. Preclinical
evaluation of RSR13 has demonstrated that doses of 100–
300 mg kg–1 achieve an increase in p50 and normal tissue pO2, a
decrease in intratumoral hypoxia, and an enhancement of radia-
tion-induced cell killing in several tumour systems (Khandelwal et
al, 1993, 1996; Teicher et al, 1996).
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Summary Pre-clinical evaluation has demonstrated that 2-[4-(((3,5-dimethylanilino)carbonyl)methyl)phenoxy]-2-methylpropionic acid
(RSR13) acts as an allosteric effector of haemoglobin (Hb). RSR13 binding to Hb results in decreased haemoglobin–oxygen (Hb–O2) affinity,
improved tumour oxygenation, and enhanced radiation-induced cell killing in several experimental tumour systems. In the present work, ex
vivo clonogenic survival analyses are applied in two murine tumour systems to characterize the relationship between the magnitude of
decrease in Hb–O2 affinity and radiosensitization, the influence of inspired pO2 upon this effect, and the efficacy of combining RSR13 and
radiation during a course of repeated radiation exposures. For FSaII tumours in C3H mice breathing air, 100 mg kg–1 RSR13 administered
intraperitoneally produced an enhancement ratio (ER) of 1.3, but there was marked desensitization at a RSR13 dose of 300 mg kg–1 (ER 0.6).
The most likely reason for the increased radioresistance was insufficient oxygen loading of Hb in the pulmonary circulation due to reduced
haemoglobin–oxygen affinity because carbogen breathing combined with 300 mg kg–1 RSR13 reversed the effect and produced an ER of 1.8.
In SCCVII tumours in C3H mice irradiated with eight fractions of 2.5 Gy over 4 days, the surviving fraction was reduced to 58–67% of control
values when RSR13 was combined with radiation on days 1 and 2, days 3 and 4, or days 1–4. These results confirm that combining RSR13
and irradiation within a fractionated course of clinically relevant low-dose exposures provides significant radiosensitization. Additional
preclinical experimentation is needed to define better the optimum dose-scheduling conditions for clinical applications.
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To optimize the efficacy of RSR13 combined with radiotherapy, it
is important to characterize the quantitative relationship between
increases in p50 and radiation-induced cytotoxicity and the effect of
inspired pO2 upon this effect. It is also essential to establish with
greater certainty the enhancement of tumour radiosensitivity within
dose schedules that combine RSR13 with repeated radiation expo-
sures, as is typical for a course of fractionated radiotherapy. The
present work addresses these issues using highly sensitive ex vivo
clonogenic survival analyses in two syngeneic murine tumour
systems, both established models of tumour hypoxia (Okunieff et al,
1986; Brown and Lemmon, 1990). For the murine FSaII fibro-
sarcoma, single-exposure radiation dose–response analyses were
generated at different doses of RSR13 and air or carbogen breathing.
The schedule dependence of RSR13 combined with repeated radia-
tion exposures in the therapeutic dose range was investigated using
SCCVII tumours.
MATERIALS AND METHODS
Preparation, dosage and administration of RSR13
RSR13 was supplied by Allos Therapeutics (Denver, CO, USA) as
a standardized stock solution of 30 mg ml–1 in 0.9% sodium chlo-
ride. RSR13 was administered intraperitoneally (i.p.) at doses of
100, 150, 200, 250 and 300 mg kg–1. This dose range was based on
previous findings that 300 mg kg–1 was a well-tolerated dose in
C3H mice, increased muscle pO2, and resulted in radiosensitiza-
tion of FSaII fibrosarcomas (Khandelwal et al, 1993, 1996).
Animals and tumour models
Male C3H mice were obtained from the Department of Radiation
Medicine at the Massachusetts General Hospital (Boston, MA,
USA). The maintenance of mice was in compliance with the NIH
1996 regulations for the care and use of laboratory animals. Two
syngeneic tumour models in C3H mice were used: the FSaII
fibrosarcoma (Okunieff et al, 1986) and the SCCVII squamous
cell carcinoma (Brown and Lemmon, 1990; Dorie et al, 1993).
FSaII tumour cells were handled as described previously
(Khandelwal et al, 1996). For SCCVII tumours, original tumour
cell stocks and protocols for tumour maintenance were kindly
provided by Dr JM Brown. Estimates of the hypoxic fraction of
SCCVII tumours have ranged from 1% to 20%, and this tumour
has been previously used in experiments involving fractionated
radiation exposures (Horsman et al, 1994; Brown and Lemmon,
1990). The percentage of radiobiological hypoxia within FSaII
tumours of a size similar to those used in the present experiments
has been reported to be in the range of 12–17% (Rice et al, 1980;
Gerweck et al, 1992).
Both tumour types were propagated by identical methodology.
Briefly, FSaII/SCCVII cells were injected into C3H mice to estab-
lish tumours from which single-cell suspensions were generated
for frozen stocks. These stocks were used to maintain relatively
short-term cultures for up to four passages. From each in vitro
passage, tumours were propagated in vivo by subcutaneous injec-
tion of 7.5 ´ 103 FSaII cells or 3 ´ 104 SCCVII cells into the right
hind leg of C3H mice.
Effects of RSR13 on Hb–O2 affinity and the oxygen
equilibrium curve
For the tonometry analyses described below, changes in Hb–O2
affinity were determined from blood samples obtained at 20, 40
and 60 min after RSR13 administration. Results were displayed in
the form of oxygen equilibrium curves (OEC) in which pO2 was
plotted against per cent of total oxygen saturation of Hb(SO2). The
reduction of Hb–O2 affinity was characterized by a right-hand shift
of the OEC and corresponds to an increase in p50. As controls
for RSR13 administration, mice were injected with identical
volumes of 0.9% sodium chloride.
For the ex vivo tonometry, RSR13 at doses of 100, 150, 200,
250 and 300 mg kg–1 was injected i.p. into mice to establish the
time course and dose–response data for the increase in p50.
Between 20 and 60 min after administration of RSR13, the mice
were killed by carbon dioxide asphyxiation, and an average of
0.3 ml of blood was collected from each mouse by cardiac punc-
ture. For each RSR13 dose and time point, heparinized blood
samples from six mice were pooled for multipoint tonometry.
Tonometry was performed using an automated blood gas
analyser and co-oximeter (Instrumentation Laboratories,
Lexington, MA, USA) against gas mixtures containing varied
oxygen concentrations of 2.95%, 5.85% and 8.75%, and a fixed
carbon dioxide concentration of 5.8% with a balance of nitrogen.
All samples were incubated at 37°C for 10 min, and Hb concentra-
tion and pH values were determined. The percent Hb saturation
with oxygen (SO2) was measured by co-oximetry. The OEC data
was fitted to a standard Hill’s equation curve by non-linear regres-
sion analyses using Scientist software (MicroMath, Salt Lake City,
UT, USA).
Radiation procedures
FSaII or SCCVII tumours were studied when the greatest tumour
diameter reached 6.5–8 mm. Non-anaesthetized, unrestrained
tumour-bearing mice received single, whole-body radiation expo-
sures at a dose rate of 1.7 Gy min–1 using a 60Co teletherapy unit.
Control animals were sham irradiated. Irradiation was adminis-
tered 20 min after i.p. injection of RSR13 or an identical volume
of 0.9% sodium chloride as control. Mice were killed by carbon
dioxide asphyxiation 18 h after administration of the assigned
treatment.
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Figure 1 RSR13/irradiation schedules for clonogenic survival analyses.
(A) Single-exposure experiments, FSaII tumours. (B) Repeated exposure
experiments, SCCVII tumours. ´, irradiation alone; *, RSR13 plus irradiation;
CF, colony formation; IR, ionizing radiation816 SR Khandelwal et al
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Clonogenic survival after RSR13-mediated
radiosensitization
The radiosensitization of tumours by RSR13 was quantified using
ex vivo clonogenic survival analyses addressing different aspects
with each of the two tumour systems. FSaII tumours were used to
correlate RSR13 dosing with increases in p50 and the relative
radiosensitization under conditions of air and carbogen breathing.
In these experiments, mice bearing FSaII tumours received i.p.
injections of saline or RSR13 at doses of 100, 200 or 300 mg kg–1
20 min before irradiation with single exposures in the dose range
of 5–15 Gy. The animals breathed air or carbogen 5 min before
and during irradiation (see below). All data points were obtained
using a minimum of four animals per combination of radiation
dose, RSR13 dose, and inspiratory gas.
SCCVII tumours were used to evaluate the impact of varying
the exposure schedule of RSR13 and radiation during a course of
repeated radiation exposures simulating a fractionated course of
radiotherapy. Mice bearing SCCVII tumours breathed carbogen
starting 5 min before and during the time of irradiation. The
animals were treated with eight exposures of 2.5 Gy given twice
daily for 4 days with a minimum 6-h interval between the two
daily radiation exposures. RSR13, 300 mg kg–1, was injected i.p.
20 min before each radiation exposure following a schedule
depicted in Figure 1.
At the time of ex vivo clonogenic survival analysis, SCCVII
tumours were excised and cut into small pieces. A pronase/
DNAase/collagenase mixture (Brown and Lemmon, 1990; Dorie
et al, 1993) was used to prepare single-cell suspensions. Cells were
plated in Waymouth’s medium supplemented with 15% fetal
bovine serum. Colonies of 50 or more cells were counted 10 days
after plating. FSaII tumours were assayed for clonogenic survival
as previously described (Khandelwal et al, 1993, 1996). For both
tumour types, the data obtained from an individual animal tumour
represents the average value of clonogenic assay performed in
quadruplicate.
Clonogenic survival statistical analyses
For FSaII tumours, linear regression was used to analyse the loga-
rithm of clonogenic survival after doses of 5–15 Gy. The enhance-
ment ratio (ER) for each treatment group was defined as follows:
ER =
radiation dose without RSR13 for 10% surviving fraction
radiation dose with RSR13 for 10% surviving fraction
A t-test was used for comparisons of the logarithms of surviving
fractions of SCCVII tumour cell after varying schedules of RSR13
administration. However, because multiple applications of that test
at the significance level of 0.05 can increase the probability of a
type I error, both the Newman–Kuels and Tukey methods of
multiple data set comparisons were also used to test for significant
differences between pairs of RSR13–radiation dose schedules.
Curves fitted by linear regression are compared by analysing the
confidence interval of the estimated slopes and intercepts. All
statistical analyses of clonogenic survival data were performed
with GraphPad Prism (GraphPad Software, San Diego, CA, USA).
RESULTS
Oxygen equilibrium curve (OEC)
The in vivo RSR13 dose–response data for Hb–O2 affinity
are illustrated by OECs in which the abscissa is pO2 and the ordi-
nate represents SO2 (Figure 2A and B). The pH and Hb concentra-
tions of the blood samples were nearly constant and did not
significantly affect the multipoint tonometry measurements. In the
pooled heparinized blood samples, the ranges (±s.d.) of pH
measurements and Hb concentrations were 7.14 (±0.03)–7.20
(±0.03) and 12.3 (±0.15)–13.0 (±0.7) g dl–1 respectively. The right-
hand shift of OEC as a function of time after RSR13 administration
of 200 and 300 mg kg–1 was initially examined at 20, 40 and 60
min. The maximum right-hand shift was observed 20 min after i.p.
administration of RSR13 with diminishing effects at 40 and 60 min
(data not shown). Because of this finding, all blood samples for
tonometric analysis were obtained 20 min after i.p. administration
of RSR13. Figure 2A illustrates the fitted OECs based on SO2
values determined at pO2 values of 20, 40 and 60 mmHg after
RSR13 doses of 100, 150, 200, 250 or 300 mg kg–1. The initial
OECs (Figure 2A) indicated that after RSR13 doses of 200–
300 mg kg–1 SO2 remained below 60% at a pO2 of 100 mmHg,
which corresponds to arterial pO2 during air breathing. To confirm
that conditions of higher pO2 provided SO2 values consistent with
near-complete Hb loading, the multipoint tonometry conditions
100
80
60
40
20
0
A B
0 2 04 06 08 0
pO2 (mmHg) pO2 (mmHg)
400 0 300 100 200 500 600 700
100
80
60
40
20
0 0
100 200 300
RSR13
H
b
  p
5
0
S
O
2
 
(
%
)
C
Figure 2 Dose-dependent effects of RSR13 on Hb–O2 affinity. (A) The OECs 20 min after i.p. administration of RSR13 to C3H mice. The curves shift to the
right as the Hb–O2 affinity decreases. RSR13 dose: 0 mg kg–1 (n); 100 mg kg–1 (l); 150 mg kg–1 (s); 200 mg kg–1 (n n); 250 mg kg–1 (l l); 300 mg kg–1 (s s). The
250 mg kg–1 and 300 mg kg–1 curves are nearly superimposed. (B) SO2 was measured at 60, 90 and ~700 mmHg 20 min after i.p. administration of RSR13 to
C3H mice. The lower values of SO2 observed at arterial pO2 (~100 mmHg) in Figure 2A were increased to near-complete saturation at pO2 of ~700 mmHg.
RSR13 dose: 200 mg kg–1 (n); 250 mg kg–1 (l), 300 mg kg–1 (s). (C) The pO2 at which Hb is 50% saturated with oxygen (p50) 20 min after RSR13
administration. The RSR13 dose–response is approximately linear in this rangeRSR13-enhanced radiation response 817
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were modified to measure SO2 at  pO2 values of 60, 90 and
approximately 700 mmHg, corresponding to the pO2 of carbogen.
Figure 2B shows that after RSR13 doses of 200–300 mg kg–1
SO2 approached 100% when Hb was exposed to carbogen. Thus,
carbogen breathing would provide effective Hb loading even
with markedly reduced Hb–O2 affinity. To quantify the right-hand
shift of the OEC for each RSR13 dose, the p50 values were
calculated and plotted over the RSR13 dose range used (Figure
2C, inset). The p50 values demonstrated an approximately linear
dose–response in the range between 100 and 300 mg kg–1 RSR13
(Figure 2C).
RSR13-induced radiosensitization of tumours
The effect of RSR13 on the radiosensitivity of hypoxic FSaII
fibrosarcomas was quantified by clonogenic survival. The ex vivo
survival analyses after single radiation exposures under conditions
of air and carbogen breathing of the mice are shown in Figure 3A
and B respectively. The radiation survival curves shown have been
generated after in vivo irradiation and administration of saline or
RSR13 at doses of 100 or 300 mg kg–1. Linear regression analyses
demonstrate that RSR13 at 100 mg kg–1 and air breathing resulted
in significant radiosensitization (P = 0.01); this effect differs from
the marked decrease in radiosensitivity at 300 mg kg–1 of RSR13,
under which condition the oxygen loading of Hb in the pulmonary
circulation could be compromised because of the expected large
reduction in Hb–O2 affinity. Figure 3B illustrates that this appar-
ently insufficient oxygen loading of Hb could be overcome by
carbogen breathing, as indicated by the finding that RSR13 at the
dose of 300 mg kg–1 combined with carbogen breathing resulted in
the most significant enhancement of radiation cytotoxicity relative
to all other treatment conditions (P = 0.0001) including carbogen
alone (P = 0.009). The calculated ER values and the surviving frac-
tion (SF) of cells relative to control conditions are listed in Table 1.
The effects of different RSR13 doses on increases in p50 and
ER under conditions of air or carbogen breathing are plotted in
Figure 4. It can be seen that the ER continues to increase with
higher RSR13 doses under conditions of carbogen breathing but
not with air breathing. Although the ER for 300 mg kg–1 carbogen
rises to 1.8 at a p50 of 40 mmHg, there is an actual diminution of
radiation-induced killing at the highest dose of RSR13 with air
breathing.
Relative RSR13 effects during repeated radiation
exposures
The potential radiosensitizing effects of RSR13 after smaller
repeated radiation exposures was examined under conditions of
300 mg kg–1 RSR13 and carbogen breathing to evaluate the
potency of RSR13-induced radiosensitization in combination with
fractionated irradiation. Mice bearing SCCVII tumours were irra-
diated to 8 ´ 2.5 Gy over 4 days, 20 min after RSR13 injection.
Four alternative schedules of combined RSR13 administration and
irradiation were compared (see Figure 1). The survival ratio (SR)
is defined as the SF obtained under a given experimental condition
divided by the SF under control conditions, as noted in the legend
in Table 2. The radiosensitizing effect of RSR13 is demonstrated
by SR values ranging from 0.58 to 0.93 relative to 1.0 for radiation
alone (Table 2). All three schedules involving RSR13 administra-
tion on consecutive days were significantly different from the
control saline injections by standard unpaired t-test. The results of
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Figure 3 The effects of RSR13, air or carbogen breathing, and radiation
dose on FSaII cell survival. Regression analysis was used to fit the
clonogenic survival data for doses of 5, 8 and 15 Gy. Data points are the
means ± s.e.m. from a minimum of four animals per condition. Solid line =
saline; dotted line = RSR13 100 mg kg–1; dashed line = RSR13 300 mg kg–1.
(A) Air breathing; (B) carbogen breathing
Figure 4 Relationship between RSR13 dose and increase in p50 and
enhancement ratio (ER) for FsaII fibrosarcoma cells. The horizontal axis
indicates RSR13 dose. Columns indicate the ER after air breathing (black) or
carbogen breathing (white), with values indicated on the left vertical axis. On
the right vertical axis are values of increase in p50; Dp50, represented
graphically as a solid line
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specialized tests for multiple comparisons are also included in
Table 2. The Newman–Kuels test confirms the observations of the
t-test, indicating that the results are valid and do not reflect random
differences that can result from comparisons of numerous data
sets. The more stringent Tukey test, which produces broader confi-
dence intervals, was also used in an effort to differentiate between
relative radiosensitizing effects of the different schedules. As indi-
cated in Table 2, the most significant difference occurred between
the controls and the schedule involving RSR13 administration on
days 1 and 2.
DISCUSSION
The present work has demonstrated that RSR13, a synthetic
allosteric effector of Hb, can emulate the function of the physiolog-
ical modifier 2,3-DPG. The multipoint tonometry on whole-blood
samples demonstrates the potent and rapid impact of RSR13 on the
OEC in vivo, reflected in a p50 increase approaching 50 mmHg
within 20 min after maximum RSR13 doses of 300 mg kg–1. This
reduction in Hb–O2 affinity has been demonstrated to result in
improved oxygen delivery to normal tissues (Khandelwal et al,
1993) and malignant tumours (Teicher et al, 1996). The increased
tumour oxygenation led to tumour radiosensitization which was
dependent upon the magnitude of increase in p50 and the atmos-
pheric pO2, as illustrated in Figures 3 and 4. Under conditions of air
breathing, enhanced radiosensitivity was observed for the FSaII
fibrosarcoma after an RSR13 dose of 100 mg kg–1, whereas a dose
of 300 mg kg–1 had a radioprotective effect. This pattern was
reversed by carbogen breathing. The radiosensitizing effect of
carbogen alone was significantly amplified by the administration of
RSR13 at doses of 100 or 300 mg kg–1.
The multifactorial aetiology of tumour hypoxia makes strategies
to overcome it challenging. Factors contributing to tumour hypoxia
are increased oxygen consumption as a result of unrestricted cell
proliferation (Nordsmark et al, 1996b) and inefficient oxygen
delivery as a consequence of widely variable interstitial pressure
gradients and irregular microvessel distribution (Jain, 1988).
Different attempts to increase oxygen delivery to tumours have
included the use of blood flow modifiers (Horsman et al, 1991) and
the use of hyperbaric oxygen (Fletcher et al, 1977; Ward and Dixon,
1979; Dische, 1983; Brady et al, 1981). Neither approach has
demonstrated consistent success in clinical trials to warrant thera-
peutic application outside investigative protocols. The radiosensi-
tizing effect demonstrated for the allosteric effector of Hb, RSR13,
supports earlier experimental work on 2,3-DPG (Siemann and
Macler, 1986) and establishes the pharmacological manipulation of
Hb–O2 affinity as a new basis for increased oxygen delivery to
tissues. The preclinical results on two tumour systems in single- and
multidose radiation administration schedules demonstrate signifi-
cant promise for RSR13 as a sensitizer of therapeutic irradiation.
There is uncertainty regarding the relative contributions to
overall tumour hypoxia of diffusion-limited oxygen gradients and
longitudinal oxygen gradients from the arterial to the venous capil-
lary bed. Although the factors limiting oxygen diffusion perpen-
dicular to the direction of blood flow through microvasculature
have been recognized and investigated, only very recently has
attention been directed to the large gradient of pO2 from the arte-
rial to the arteriolar circulation, a potential decrease of 50–70% in
normal and tumour tissues (Dewhirst et al, 1996). Given the mech-
anism of decreasing Hb–O2 affinity by RSR13, it is likely that the
drug will be most influential at the arteriole–capillary interface by
facilitating release of oxygen from partially depleted Hb. Because
there is a steep gradient of pO2 from the arterial to the arteriolar
circulation, it is essential to have maximal oxygen loading within
the pulmonary capillary circulation. With extreme increases in
p50, such as those achieved by an RSR13 dose of 300 mg kg–1, air
breathing exerted a radioprotective effect due to insufficient satu-
ration of Hb with oxygen in the pulmonary venous circulation.
Consequently, peripheral delivery of oxygen was compromised,
exacerbating the degree of tumour hypoxia. Because the high
inspiratory pO2 values associated with carbogen breathing can
provide near-complete saturation of Hb (Figure 1B), the potential
advantages of reduced Hb–O2 affinity can be exploited to enhance
radiosensitivity in tumour tissues.
Although the present experiments with FSaII tumours were not
designed to estimate the hypoxic fraction, it is possible to estimate
the change in the hypoxic fraction in these tumours from the
clonogenic survival data. In other studies, the fraction of radiobio-
logically hypoxic tumour cells has been determined by comparing
ex vivo survival data after in vivo irradiation of tumours under
Table 2 The effect of RSR13 administration on the survival of irradiated SCCVII tumour cells receiving a course of fractionated radiation doses (8 ´ 2.5 Gy
in 4 days)
Treatment/day(s) Number of SF SR P-value P-value P-value
animals (t-test) (Newman– (Tukey)
Kuels)
Saline/1–4 22 0.0564 1.00 – – –
RSR13/1,2 21 0.0326 0.58 0.0003 <0.01 <0.01
RSR13/3,4 23 0.0362 0.64 0.0031 <0.05 <0.05
RSR13/1–4 20 0.0378 0.67 0.0230 <0.05 NS
RSR13/1,4 14 0.0526 0.93 NS NS NS
SF = surviving fraction; SR = survival ratio = SFRSR13 treatment/SFsaline control; NS = not significant.
Table 1 Results of FSaII tumour single-exposure cell survival curves:
RSR13 dose–response and effects of air vs. carbogen breathing
Inspiratory gas Air Carbogen
RSR13 dose (mg kg–1) 0 100 300 0 100 300
ER 1.0 1.27 0.62 1.24 1.35 1.75
SF15 0.069 0.031 0.160 0.026 0.021 0.005
ER = enhancement ratios (see Materials and methods section); SF15 =
surviving fraction after 15 Gy.RSR13-enhanced radiation response 819
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non-perturbed conditions and conditions of complete hypoxia
typically achieved by clamping the arterial supply (Moulder and
Rockwell, 1984). In the dose range above 10 Gy, cell survival is
expected to be almost completely dependent on the presence of
hypoxic cells; the fraction of hypoxic cells can be estimated by
determining the vertical distance of the parallel lines fitted to data
plotted on a semilog graph. The curves in Figure 3 fitted by linear
regression are not parallel because they include data from 5- and 8-
Gy dose points, and a substantial proportion of fully oxygenated
cells could survive this dose. However, listed in Table 1 are the
surviving fraction (SF) values obtained after 15 Gy, at which dose
the number of surviving cells should predominantly reflect the
initial burden of hypoxic cells. Comparison of the SF under
control conditions with those obtained under the various experi-
mental conditions reveals that air breathing with 100 mg kg–1
RSR13 reduces the SF to 0.031 from the control value of 0.069,
consistent with a 55% reduction of hypoxic cells. Likewise,
carbogen breathing with 100 mg kg–1 or 300 mg kg–1 RSR13
reduces the hypoxic fraction by approximately 70% and 93%
respectively.
The other key aspect of RSR13-mediated radiosensitization
examined in this study was the effect of RSR13 administration
during a course of repeated radiation exposures. Using the SCCVII
tumour model, RSR13 given at a dose of 300 mg kg–1 with
carbogen breathing during at least 2 consecutive days of the irradi-
ation scheme (see Figure 1) resulted in significant radiosensitiza-
tion relative to radiation alone, providing a 33–42% enhancement
of cytotoxicity (Table 2). Although others have used SCCVII
tumours to evaluate the relative timing of radiation and other
hypoxic cell radiosensitizers (Brown and Lemmon, 1990), the
tumour model has not been applied previously to agents that
enhance oxygen delivery. The results from our present study
suggest that the radiosensitization of RSR13 is greatest when
administered during the first half of the treatment course. These
results are compatible with changes in tumour oxygenation
expected to occur after irradiation alone and have been previously
described as radiation-induced reoxygenation (Van Putten and
Kallman, 1968). However, the pattern of reoxygenation can be
variable (Goda et al, 1995), and further estimation of radiation-
induced changes of tumour oxygenation under the present condi-
tions of repeated radiation exposures will be required.
It is also noteworthy that RSR13 administered during the
second half of the course of repeated radiation exposures still
provides a significant 36% radiosensitization, suggesting the
continued presence of hypoxic cells. One contributing factor to
these findings may be the relatively short course of simulated frac-
tionated irradiation over only 4 days, which is unlikely to allow for
effective reoxygenation. Therefore, findings from the present
study are currently being extended using a more protracted, once-
daily irradiation schedule. Such studies are important because of
their bearing on the design of clinical trials attempting to demon-
strate a benefit for combined administration of RSR13 and
radiation relative to irradiation alone. A phase IB tolerance study
in human cancer patients has established that repeated daily
100 mg kg–1 doses of RSR13 may be safely administered intra-
venously during a 2-week course of fractionated radiotherapy and
that the agent exerts measurable increases in p50 (Kavanagh et al,
1997). However, for a more protracted course of radiotherapy in a
potentially curative situation, it might be desirable to use RSR13
for only a portion of the entire treatment course; consequently, it is
important to identify the portion during which RSR13 will provide
the greatest benefit. Our observation of schedule-dependent vari-
ability in the magnitude of RSR13-mediated radiosensitization
suggests that additional studies are needed to define the schedule
of RSR13/radiation co-administration that yields maximum
radiosensitization.
In summary, RSR13 enhances the toxicity of radiation towards
two hypoxic tumour systems in vivo after single or repeated radia-
tion exposures. Our results illustrate the importance of Hb loading
with oxygen for the highly effective allosteric effector of Hb,
RSR13, and the degree of reduction of Hb–O2 affinity for effective
radiosensitization. Additionally, the present study shows that the
scheduling of RSR13 with radiation affects the magnitude of
RSR13-mediated radiosensitization. Combining RSR13 with radi-
ation earlier in a course of fractionated irradiation might yield the
most pronounced effect by diminishing the burden of hypoxic
cells during subsequent radiation exposures.
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